BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bienkowski M, Berghoff AS, Marosi C, Wöhrer A, Heinzl H, Hainfellner JA, Preusser M. Clinical Neuropathology practice guide 5-2015: MGMT methylation pyrosequencing in glioblastoma: unresolved issues and open questions. Clin Neuropathol 2015;34:250-7. [PMID: 26295302 DOI: 10.5414/np300904] [Cited by in Crossref: 31] [Cited by in F6Publishing: 20] [Article Influence: 5.2] [Reference Citation Analysis]
Number Citing Articles
1 Poon MTC, Keni S, Vimalan V, Ip C, Smith C, Erridge S, Weir CJ, Brennan PM. Extent of MGMT promoter methylation modifies the effect of temozolomide on overall survival in patients with glioblastoma: a regional cohort study. Neurooncol Adv 2021;3:vdab171. [PMID: 34988453 DOI: 10.1093/noajnl/vdab171] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Caccese M, Simonelli M, Villani V, Rizzato S, Ius T, Pasqualetti F, Russo M, Rudà R, Amoroso R, Bellu L, Bertorelle R, Cavallin F, Dipasquale A, Carosi M, Pizzolitto S, Cesselli D, Persico P, Casini B, Fassan M, Zagonel V, Lombardi G. Definition of the Prognostic Role of MGMT Promoter Methylation Value by Pyrosequencing in Newly Diagnosed IDH Wild-Type Glioblastoma Patients Treated with Radiochemotherapy: A Large Multicenter Study. Cancers 2022;14:2425. [DOI: 10.3390/cancers14102425] [Reference Citation Analysis]
3 Klughammer J, Kiesel B, Roetzer T, Fortelny N, Nemc A, Nenning KH, Furtner J, Sheffield NC, Datlinger P, Peter N, Nowosielski M, Augustin M, Mischkulnig M, Ströbel T, Alpar D, Ergüner B, Senekowitsch M, Moser P, Freyschlag CF, Kerschbaumer J, Thomé C, Grams AE, Stockhammer G, Kitzwoegerer M, Oberndorfer S, Marhold F, Weis S, Trenkler J, Buchroithner J, Pichler J, Haybaeck J, Krassnig S, Mahdy Ali K, von Campe G, Payer F, Sherif C, Preiser J, Hauser T, Winkler PA, Kleindienst W, Würtz F, Brandner-Kokalj T, Stultschnig M, Schweiger S, Dieckmann K, Preusser M, Langs G, Baumann B, Knosp E, Widhalm G, Marosi C, Hainfellner JA, Woehrer A, Bock C. The DNA methylation landscape of glioblastoma disease progression shows extensive heterogeneity in time and space. Nat Med 2018;24:1611-24. [PMID: 30150718 DOI: 10.1038/s41591-018-0156-x] [Cited by in Crossref: 101] [Cited by in F6Publishing: 97] [Article Influence: 25.3] [Reference Citation Analysis]
4 Chelliah SS, Paul EAL, Kamarudin MNA, Parhar I. Challenges and Perspectives of Standard Therapy and Drug Development in High-Grade Gliomas. Molecules 2021;26:1169. [PMID: 33671796 DOI: 10.3390/molecules26041169] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Teuber-Hanselmann S, Worm K, Macha N, Junker A. MGMT-Methylation in Non-Neoplastic Diseases of the Central Nervous System. Int J Mol Sci 2021;22:3845. [PMID: 33917711 DOI: 10.3390/ijms22083845] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Yuan G, Niu L, Zhang Y, Wang X, Ma K, Yin H, Dai J, Zhou W, Pan Y. Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients. J Neurooncol 2017;133:193-201. [PMID: 28516344 DOI: 10.1007/s11060-017-2433-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
7 Arora A, Somasundaram K. Glioblastoma vs temozolomide: can the red queen race be won? Cancer Biol Ther 2019;20:1083-90. [PMID: 31068075 DOI: 10.1080/15384047.2019.1599662] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
8 Sailer V, Holmes EE, Gevensleben H, Goltz D, Dröge F, de Vos L, Franzen A, Schröck F, Bootz F, Kristiansen G, Schröck A, Dietrich D. PITX2 and PANCR DNA methylation predicts overall survival in patients with head and neck squamous cell carcinoma. Oncotarget 2016;7:75827-38. [PMID: 27716615 DOI: 10.18632/oncotarget.12417] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
9 Panagopoulos I, Gorunova L, Leske H, Niehusmann P, Johannessen LE, Staurseth J, Øino N, Meling TR, Heim S, Micci F, Brandal P. Pyrosequencing Analysis of MGMT Promoter Methylation in Meningioma. Cancer Genomics Proteomics 2018;15:379-85. [PMID: 30194078 DOI: 10.21873/cgp.20096] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
10 Siller S, Lauseker M, Karschnia P, Niyazi M, Eigenbrod S, Giese A, Tonn JC. The number of methylated CpG sites within the MGMT promoter region linearly correlates with outcome in glioblastoma receiving alkylating agents. Acta Neuropathol Commun 2021;9:35. [PMID: 33663593 DOI: 10.1186/s40478-021-01134-5] [Reference Citation Analysis]
11 Bodensohn R, Corradini S, Ganswindt U, Hofmaier J, Schnell O, Belka C, Niyazi M. A prospective study on neurocognitive effects after primary radiotherapy in high-grade glioma patients. Int J Clin Oncol 2016;21:642-50. [PMID: 26694815 DOI: 10.1007/s10147-015-0941-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
12 Mansouri A, Hachem LD, Mansouri S, Nassiri F, Laperriere NJ, Xia D, Lindeman NI, Wen PY, Chakravarti A, Mehta MP, Hegi ME, Stupp R, Aldape KD, Zadeh G. MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges. Neuro Oncol 2019;21:167-78. [PMID: 30189035 DOI: 10.1093/neuonc/noy132] [Cited by in Crossref: 55] [Cited by in F6Publishing: 59] [Article Influence: 27.5] [Reference Citation Analysis]
13 Wongsurawat T, Jenjaroenpun P, De Loose A, Alkam D, Ussery DW, Nookaew I, Leung YK, Ho SM, Day JD, Rodriguez A. A novel Cas9-targeted long-read assay for simultaneous detection of IDH1/2 mutations and clinically relevant MGMT methylation in fresh biopsies of diffuse glioma. Acta Neuropathol Commun 2020;8:87. [PMID: 32563269 DOI: 10.1186/s40478-020-00963-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
14 Radke J, Koch A, Pritsch F, Schumann E, Misch M, Hempt C, Lenz K, Löbel F, Paschereit F, Heppner FL, Vajkoczy P, Koll R, Onken J. Predictive MGMT status in a homogeneous cohort of IDH wildtype glioblastoma patients. Acta Neuropathol Commun 2019;7:89. [PMID: 31167648 DOI: 10.1186/s40478-019-0745-z] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
15 Nguyen N, Redfield J, Ballo M, Michael M, Sorenson J, Dibaba D, Wan J, Ramos GD, Pandey M. Identifying the optimal cutoff point for MGMT promoter methylation status in glioblastoma. CNS Oncol 2021;10:CNS74. [PMID: 34486380 DOI: 10.2217/cns-2021-0002] [Reference Citation Analysis]
16 Quillien V, Lavenu A, Ducray F, Joly MO, Chinot O, Fina F, Sanson M, Carpentier C, Karayan-Tapon L, Rivet P, Entz-Werle N, Legrain M, Zalcman EL, Levallet G, Escande F, Ramirez C, Chiforeanu D, Vauleon E, Figarella-Branger D. Validation of the high-performance of pyrosequencing for clinical MGMT testing on a cohort of glioblastoma patients from a prospective dedicated multicentric trial. Oncotarget 2016;7:61916-29. [PMID: 27542245 DOI: 10.18632/oncotarget.11322] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 7.0] [Reference Citation Analysis]
17 Estival A, Sanz C, Ramirez JL, Velarde JM, Domenech M, Carrato C, de Las Peñas R, Gil-Gil M, Sepúlveda J, Armengol R, Cardiel I, Berrocal A, Luque R, Herrero A, Balana C. Pyrosequencing versus methylation-specific PCR for assessment of MGMT methylation in tumor and blood samples of glioblastoma patients. Sci Rep 2019;9:11125. [PMID: 31366977 DOI: 10.1038/s41598-019-47642-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
18 Rosas-Alonso R, Colmenarejo-Fernandez J, Pernia O, Rodriguez-Antolín C, Esteban I, Ghanem I, Sanchez-Cabrero D, Losantos-Garcia I, Palacios-Zambrano S, Moreno-Bueno G, de Castro J, Martinez-Marin V, Ibanez-de-Caceres I. Clinical validation of a novel quantitative assay for the detection of MGMT methylation in glioblastoma patients. Clin Epigenetics 2021;13:52. [PMID: 33750464 DOI: 10.1186/s13148-021-01044-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
19 Wenger A, Ferreyra Vega S, Kling T, Bontell TO, Jakola AS, Carén H. Intratumor DNA methylation heterogeneity in glioblastoma: implications for DNA methylation-based classification. Neuro Oncol 2019;21:616-27. [PMID: 30668814 DOI: 10.1093/neuonc/noz011] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 18.5] [Reference Citation Analysis]
20 Chai RC, Zhang KN, Liu YQ, Wu F, Zhao Z, Wang KY, Jiang T, Wang YZ. Combinations of four or more CpGs methylation present equivalent predictive value for MGMT expression and temozolomide therapeutic prognosis in gliomas. CNS Neurosci Ther 2019;25:314-22. [PMID: 30117294 DOI: 10.1111/cns.13040] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
21 McAleenan A, Kelly C, Spiga F, Kernohan A, Cheng HY, Dawson S, Schmidt L, Robinson T, Brandner S, Faulkner CL, Wragg C, Jefferies S, Howell A, Vale L, Higgins JPT, Kurian KM. Prognostic value of test(s) for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide. Cochrane Database Syst Rev 2021;3:CD013316. [PMID: 33710615 DOI: 10.1002/14651858.CD013316.pub2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
22 Johannessen LE, Brandal P, Myklebust TÅ, Heim S, Micci F, Panagopoulos I. MGMT Gene Promoter Methylation Status - Assessment of Two Pyrosequencing Kits and Three Methylation-specific PCR Methods for their Predictive Capacity in Glioblastomas. Cancer Genomics Proteomics 2018;15:437-46. [PMID: 30343277 DOI: 10.21873/cgp.20102] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]